Budesonide for Maintenance Treatment of Collagenous Colitis
NCT ID: NCT00180076
Last Updated: 2010-03-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
75 participants
INTERVENTIONAL
2004-07-31
2008-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Budesonide Treatment for Lymphocytic Colitis
NCT00180050
Long-Term Treatment of Collagenous Colitis With Budesonide
NCT00139165
Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis
NCT00450086
Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis
NCT01209208
9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease
NCT01086553
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Budesonide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diarrhea
* written informed consent
Exclusion Criteria
* other inflammatory bowel diseases
* history of colonic surgery
* celiac disease
* malignancies
* severe concomitant diseases
* use of budesonide, steroids, mesalazine within the previous 2 weeks
* known intolerance to budesonide
* history of lack of response to budesonide
* pregnancy,lactation
* drug and/or alcohol abuse
* lack of compliance
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Technische Universität Dresden
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stephan Miehlke, Prof.
Role: PRINCIPAL_INVESTIGATOR
Medical Department I, Technical University Hospital, Dresden, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Department I, Technical University Hospital
Dresden, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MIMIC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.